Non-Alcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome: A Systematic Review, Meta-Analysis, and Meta-Regression
Journal of Clinical Medicine · 20.01.2023 · 12 (3) · 856
DOI: 10.3390/jcm12030856 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.01.2023. Verfasst von Ramiro Manzano-Nunez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The metabolic effects of polycystic ovary syndrome (PCOS) may increase the risk of non-alcoholic fatty liver disease (NAFLD). However, the burden of NAFLD in PCOS has not been unequivocally defined. This systematic review (SR), meta-analysis (MA) assessed NAFLD’s prevalence, and risk factors in patients with PCOS.
Methods
A literature search was performed in MEDLINE, Scopus, and Scielo. First, we performed a MA of proportions to estimate the prevalence of NAFLD in PCOS. Second, we performed meta-analyses of precalculated adjusted odds ratios to examine NAFLD risk factors. Finally, we performed a meta-regression to model how the estimated prevalence changed with changes in prespecified variables.
Results
We identified 817 articles from the database searches. Thirty-six were included. MA of proportions found a pooled NAFLD prevalence of 43% (95% CI, 35–52%) with high heterogeneity (I2 = 97.2%). BMI, waist circumference, ALT values, HOMA-IR values, free androgen index levels, hyperandrogenism, and triglycerides were associated with significantly higher risk-adjusted odds of NAFLD among patients with PCOS. Meta-regression showed that rises in NAFLD prevalence were mediated through increases in metabolic syndrome prevalence and higher levels of HOMA-IR, free androgen index, and total testosterone.
Conclusion
The prevalence of NAFLD (43%) among PCOS patients is high despite their average young age, with several metabolic and PCOS-specific factors influencing its occurrence. Screening programs may aid in detecting metabolic-associated fatty liver disease and prevent its consequences. Further work is required to establish the burden of liver-related outcomes once NAFLD has progressed in the PCOS population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liver Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
- Vall d'Hebron Institute for Research, 08035 Barcelona, Spain.
- Faculty of Medicine, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
- Gynecology and Obstetrics Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
- Department of Hepatology & Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, 10117 Berlin, Germany.
- Centros de Investigación Biomédica en Red, Enfermedades Hepáticas y Digestivas (CIBERehd), 28029 Madrid, Spain.
ORCID-Profile: Marta Santana-Dominguez, Jesus Rivera-Esteban, Elena Sena, Frank Tacke
Zitieren
APA
Manzano-Nunez, R., Santana-Dominguez, M., Rivera-Esteban, J., Sabiote, C., Sena, E., Bañares, J., Tacke, F., & Pericàs, J. M. (2023). Non-Alcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome: A Systematic Review, Meta-Analysis, and Meta-Regression. Journal of Clinical Medicine, 12(3), 856. https://doi.org/10.3390/jcm12030856
Vancouver
Manzano-Nunez R, Santana-Dominguez M, Rivera-Esteban J, Sabiote C, Sena E, Bañares J, et al. Non-Alcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome: A Systematic Review, Meta-Analysis, and Meta-Regression. Journal of Clinical Medicine. 2023;12(3):856. doi:10.3390/jcm12030856
BibTeX
@article{ManzanoNunez2023,
author = {Manzano-Nunez, Ramiro and Santana-Dominguez, Marta and Rivera-Esteban, Jesus and Sabiote, Clara and Sena, Elena and Bañares, Juan and Tacke, Frank and Pericàs, Juan M},
title = {Non-Alcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome: A Systematic Review, Meta-Analysis, and Meta-Regression},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {3},
pages = {856},
doi = {10.3390/jcm12030856}
}
EUVIMED